Vancouver, British Columbia–(Newsfile Corp. – October 18, 2024) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (“PreveCeutical” or the “Company”), Health Sciences The company, which develops innovative options for preventive and therapeutic therapies using organic and nature-identical products, uses Toronto-based Phoenix Corporate Finance Inc. (“Phoenix”) as an advisor to provide strategic and corporate advisory services. We are pleased to announce that we are now offering it. In connection with potential future transactions.
Pursuant to this agreement, Phoenix has agreed to provide corporate advisory services to the Company in connection with one or more potential strategic transactions, including the potential acquisition or disposition of assets. In consideration for the Services, we have agreed to pay Phoenix a total of $30,000 plus applicable taxes.
“As PreveCeutical moves from research and development to the clinical stage, moving forward we need strategic partnerships and how we approach each of our four research programs,” said Steven Van Deventer, Chairman and CEO. In the coming months, we will be devoting additional resources and talent to each of our different programs specific to each therapeutic area.”
About PreveCeutical
PreveCeutical is a health science company that develops innovative options for preventive and therapeutic therapies using organic and nature-identical products.
PreveCeutical aims to be a leader in preventive health science and currently has five research and development programs. Sol-gel program. Nature Identical™ peptides used to treat various diseases. Non-addictive analgesic peptides as an alternative to highly addictive analgesics such as morphine, fentanyl, and oxycodone. and therapeutic products to treat athletes suffering from concussions (mild traumatic brain injuries). For more information about PreveCeutical, visit www.PreveCeutical.com and follow us on Twitter. http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About Phoenix Corporate Finance Co., Ltd.
Phoenix Corporate Finance Inc. is an independent mid-market corporate finance company serving the alternative and secondary financing needs of Canadian-based businesses. Phoenix’s purpose is to provide its client companies with an optimal number of financing options, beyond those offered by banks and other financial institutions. Phoenix specializes in underwriting and raising equity and debt financing from non-institutional and private capital sources. For more information about Phoenix corporate, commercial and ICI real estate financing activities, please visit www.phoenixcorpfinance.ca.
story continues
On behalf of the Board of Directors,
PreveCeutical Medical Inc.
“Steven Van Deventer”
Chairman and CEO
For more information, please contact us below.
Stephen Van Deventer
(604) 306-9669
ir@PreveCeutical.com
Forward-looking statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact, regarding activities, events or developments that we believe, expect or foresee will occur or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding potential acquisition or disposition transactions. Forward-looking statements reflect management’s current expectations based on currently available information and may differ materially from the results discussed in the forward-looking statements, including unfavorable market conditions and other factors beyond its control. They are subject to numerous risks and uncertainties that could cause different results. of the parties involved. Although the Company believes that the assumptions underlying forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, therefore, are subject to their inherent uncertainties. , you should not place undue reliance on such statements. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond our control. regulations or policies affecting the biotechnology or pharmaceutical industry that adversely affect PreveCeutical’s or BioGene’s future results or performance; The Company may not be able to execute the proposed trading plan, and the Company determines that the proposed transaction is not an optimal strategy. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227133.
